VOLT-AF IDE Clinical Study
NCT06223789
Arrhythmias, Cardiac, Atrial Arrhythmia
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT04045639
This is a trial to assess the effectiveness of an atrial fibrillation (AF) risk prediction algorithm and diagnostic test for the identification of patients with atrial fibrillation
Looking for future studies?
Notify Me30 year and older
All sexes
Observational
Local Institution, Ludlow, United Kingdom
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Practice inclusion criteria for the trial are as follows;
Exclusion criteria
Time frame: From the first collection of patient medical records at the beginning of the trial to the last collection of patient records following the intervention at the end of the trial (Up to 6 months)
Prevalence of AF in the research window assessed
Time frame: Up to 6 months
Time frame: Up to 6 months
Time frame: Up to 6 months
Bristol-Myers Squibb
Industry
A Randomised Controlled Trial for the Identification of Undiagnosed Atrial Fibrillation Patients Using a Machine Learning Risk Prediction Algorithm and Diagnostic Test
Acronym: PULsE AI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06223789
Arrhythmias, Cardiac, Atrial Arrhythmia
Birmingham, Alabama, United States
View Trial DetailsNCT05159492
Arrhythmias, Cardiac, Atrial Fibrillation
Graz, Austria
View Trial DetailsNCT07741682
Arrhythmias, Cardiac, Atrial Fibrillation
Qingdao, Shandong, China
View Trial DetailsNCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial Details